糖尿病前期
医学
吡格列酮
内科学
糖尿病
人口
曲线下面积
接收机工作特性
心理干预
空腹血糖受损
2型糖尿病
糖耐量受损
内分泌学
环境卫生
精神科
作者
Xiantong Zou,Yingying Luo,Qi Huang,Zhanxing Zhu,Yufeng Li,Xiuying Zhang,Xianghai Zhou,Linong Ji
摘要
Abstract Aim To investigate whether stratifying participants with prediabetes according to their diabetes progression risks (PR) could affect their responses to interventions. Methods We developed a machine learning‐based model to predict the 1‐year diabetes PR (ML‐PR) with the least predictors. The model was developed and internally validated in participants with prediabetes in the Pinggu Study (a prospective population‐based survey in suburban Beijing; n = 622). Patients from the Beijing Prediabetes Reversion Program cohort (a multicentre randomized control trial to evaluate the efficacy of lifestyle and/or pioglitazone on prediabetes reversion; n = 1936) were stratified to low‐, medium‐ and high‐risk groups using ML‐PR. Different effect of four interventions within subgroups on prediabetes reversal and diabetes progression was assessed. Results Using least predictors including fasting plasma glucose, 2‐h postprandial glucose after 75 g glucose administration, glycated haemoglobin, high‐density lipoprotein cholesterol and triglycerides, and the ML algorithm XGBoost, ML‐PR successfully predicted the 1‐year progression of participants with prediabetes in the Pinggu study [internal area under the curve of the receiver operating characteristic curve 0.80 (0.72–0.89)] and Beijing Prediabetes Reversion Program [external area under the curve of the receiver operating characteristic curve 0.80 (0.74–0.86)]. In the high‐risk group pioglitazone plus intensive lifestyle therapy significantly reduced diabetes progression by about 50% at year l and the end of the trial in the high‐risk group compared with conventional lifestyle therapy with placebo. In the medium‐ or low‐risk group, intensified lifestyle therapy, pioglitazone or their combination did not show any benefit on diabetes progression and prediabetes reversion. Conclusions This study suggests personalized treatment for prediabetes according to their PR is necessary. ML‐PR model with simple clinical variables may facilitate personal treatment strategies in participants with prediabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI